Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWKH
- Development stage
- Phase 3
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
01
Overview
DWKH is a small molecule drug initially developed by Daewon Pharmaceutical Co., Ltd. It is being investigated primarily for infectious diseases and respiratory diseases, with active indication in respiratory tract infections. The drug's mechanism of action and detailed pharmacology are not publicly disclosed. Its global highest research and development status is pending, with clinical trials reaching Phase 3, including a completed randomized, double-blind, parallel, multicenter active-controlled trial evaluating its efficacy and safety in respiratory tract infections. No regulatory approvals have been reported yet.[1][4]
- Brand names
- Codaewon S
- Other names
- DWKH
02
Targets
HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on DWKH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWKH.